Struggling with Increased Sensitivity: PSMA PET/CT - Michael Hofman

Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.   (Length of video ~ 23 minutes)

Michael Hofman discusses PSMA as the new “gold standard” and how it is significantly superior to existing imaging modalities through case studies from the Peter MacCallum Cancer Centre and a review of abstracts.

Related content:
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.

AUA 2017: 11C-Choline versus 68ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: results from a large, multi-institutional salvage lymph node dissection series


Biography: Professor Michael Hofman is a nuclear medicine physician in the Centre for Cancer Imaging at the Peter MacCallum Cancer in Melbourne. He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and radionuclide therapy.

Professor Hofman has a vision of improving patient outcomes by using molecular imaging to non-invasively characterize disease thereby enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has a particular interest in novel PET radiotracers, including F-18 and Ga-68, and theranostic applications including neuroendocrine and prostate cancers. Currently, he is the principal investigator of a randomized multi-center trial of PSMA PET/CT in PET/CT, a prospective trial of Lu-177 PSMA therapy and a prospective trial investigating the role of PET V/Q scanning in patients with lung cancer.
 
Professor Hofman previously completed a clinical and research fellowship at Guys and St Thomas in London. He is a fellow of the International Cancer Imaging Society (ICIS) and serves on the editorial board of Cancer Imaging, Leukaemia Lymphoma and the Journal of Medical Imaging and Radiation Oncology (JMIRO). He is an inaugural scientific member of the Australasian Radiopharmaceutical Trials Network (ARTnet).



E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe